By conducting cell viability assays in PC-3 and LNCaP cells (Figure 1), the results show non-specific binding with 177Lu on LNCaP cell and 177Lu-PSMA-NARI-56 on PC-3 cell, and we deepen our understanding of how this drug has specific effects on special cells and enhances its therapeutic role due to the albumin in extended prostate cancer treatment. This evidence concerns the gene FOLH1 and prostate carcinoma.